EODData

MEMBERSHIP REGISTER LOG IN

FRA, MYD: Myriad Genetics Inc

25 Mar 2026
LAST:

3.940

CHANGE:
 0.02		OPEN:
3.940		HIGH:
3.940		ASK:
0.000		VOLUME:
768
CHG(%):
0.51		PREV:
3.960		LOW:
3.940		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
25 Mar 263.9403.9403.9403.940768
24 Mar 263.9603.9603.9603.960768
23 Mar 263.9404.1203.9404.120768
20 Mar 264.0604.0604.0604.060200
19 Mar 264.0004.0004.0004.0000
18 Mar 264.1004.1004.1004.1000
17 Mar 263.9403.9403.9403.9400
16 Mar 264.0404.0404.0404.0400
13 Mar 264.1804.2804.1804.2800
12 Mar 264.3404.3404.3404.340281

PROFILE

Name:Myriad Genetics Inc
About:Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Sector:Healthcare
Address:322 North 2200 West, Salt Lake City, UT, United States, 84116
Website:https://www.myriad.com
ISIN:US62855J1043
LEI:52990044IHUOUMETT163

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-4.04 
Forward P/E:21.92 
PEG Ratio:21.92 
Price to Sales:0.65 
Price to Book:0.97 
Profit Margin:-0.49 
Operating Margin:-0.11 
Return on Assets:-0.06 
Return on Equity:-0.73 
EPS Ratio:-0.68 
Revenue:701.09M 
Shares:45.73M 
Market Cap:180.19M 

TECHNICAL INDICATORS

MA5:4.021.9%
MA10:4.083.5%
MA20:4.175.7%
MA50:4.3710.8%
MA100:5.1530.7%
MA200:5.1931.6%
RSI14:30.56 
WPR14:-100.00 
MTM14:-0.42
ROC14:-0.10 
ATR:0.12 
Week High:4.124.6%
Week Low:3.940.0%
Month High:4.5014.2%
Month Low:3.9431.6%
Year High:9.13131.8%
Year Low:3.2919.7%
Volatility:86.57